BioArctic AB (BIOA_B) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bioarctic Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.040 Welcome to BioArctic Q3 Report 2025. For the first part of the conference 00:00:05.040 -- 00:00:08.006 call, the participants will be in listen-only mode. 00:00:08.006 -- 00:00:12.634 During the questions and answers session, participants are able to ask questions by dialing 00:00:12.634 -- 00:00:18.205 pound key 5 on their telephone keypad. Now I will hand the conference over to CEO 00:00:18.205 -- 00:00:21.832 Gunala Oswald, CFO Anders Martin Loft, and colleagues. 00:00:21.832 -- 00:00:24.312 Please go ahead. 00:00:25.377 -- 00:00:30.271 Thank you. Good morning and welcome to Bioartic's presentation for the third quarter 00:00:30.271 -- 00:00:31.976 of 2025. 00:00:31.976 -- 00:00:36.312 Bioartic is continuing in a great way in our new era. 00:00:36.312 -- 00:00:42.078 with yet another quarter where we see more and more patients are getting access to Lekembe. 00:00:42.078 -- 00:00:47.203 And we are broadening our collaborations, utilizing our brain transporter technology. 00:00:47.203 -- 00:00:51.947 And we are also broadening our portfolio with new projects and new modalities. 00:00:51.947 -- 00:00:55.171 And we will talk more about that in today's presentation. 00:00:55.171 -- 00:00:57.453 Next slide, please. 00:00:57.453 -- 00:01:01.637 Biotic is listed at nasdaq.com large cap, and this is our disclaimer. 00:01:01.637 -- 00:01:03.768 Next slide, please. 00:01:03.768 -- 00:01:08.796 So I'm Gunilla Osvald and I'm the CEO of Bioartic and I will share today's presentation 00:01:08.796 -- 00:01:14.304 with our CFO Anders Martin Lööf and our Chief R&D Officer Johanna Felting 00:01:14.304 -- 00:01:17.830 and our Chief Commercial Officer Anna-Kaja Grönblad. 00:01:17.830 -- 00:01:20.370 Next slide please. 00:01:20.373 -- 00:01:25.101 So...